Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure

scientific article

Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1365-2125.1989.TB03504.X
P932PMC publication ID1379969
P698PubMed publication ID2673315
P5875ResearchGate publication ID20483547

P2093author name stringEdgar B
Wesseling H
Dunselman PH
Kuntze CE
Scaf AH
P2860cites workVariability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in manQ70702521
Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failureQ71249271
Dynamic dialysis as a method for studying protein binding. I. Factors affecting the kinetics of dialysis through a cellophane membraneQ71409528
Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stressQ34118763
First-pass elimination. Basic concepts and clinical consequencesQ34257205
The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administrationQ34397660
Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjectsQ34620868
Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic dataQ36610571
Efficacy of felodipine in congestive heart failureQ41981403
The first pass metabolism of nifedipine in man.Q42531423
The effect of nisoldipine on apparent liver blood flow and effective renal plasma flowQ43128643
The trans-hepatic extraction of nifedipineQ43229022
Commentary: a physiological approach to hepatic drug clearanceQ43996648
Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.Q52672658
Felodipine kinetics in healthy men.Q54117719
Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses.Q54407139
Vascular selectivity of felodipine.Q54457513
Treatment of essential hypertension with felodipine in combination with a diureticQ68877420
Effects of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patientsQ68986268
Comparison of high-selectivity gas chromatographic methods, including column switching, for the determination of felodipine in plasmaQ69140789
Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patientsQ69443400
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectpharmacokineticsQ323936
heart failureQ181754
congestive heart failureQ19000661
P304page(s)45-52
P577publication date1989-07-01
P1433published inBritish Journal of Clinical PharmacologyQ176044
P1476titlePharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure
P478volume28

Reverse relations

cites work (P2860)
Q36115910Clinical pharmacokinetics of calcium antagonists. An update
Q38076347Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).
Q38253565Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).
Q28325479Felodipine Clinical Pharmacokinetics
Q35336765Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders
Q28325222Felodipine: A New Dihydropyridine Calcium-Channel Antagonist
Q44247783Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment
Q34618855Racemic therapeutics--ethical and regulatory aspects
Q71149787Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients